NCT07781631
A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood
StatusActive, Not Recruiting
PhasePhase 1
SponsorBoehringer Ingelheim
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Site details revised
- Notable Recruitment opened
- Eligibility criteria expanded, about 9 words
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Timeframe: Up to 40 days.
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Timeframe: Up to 40 days.
Secondary (1)
Minimum concentration of the analyte in plasma at steady state within a uniform dosing interval τ (Cmin,ss)
Arms and interventions
Verducatib, then verducatib + carbamazepineExperimental
Fixed-sequence treatment for all trial participants.
Drugs: Verducatib, Carbamazepine
Sites
1 site in 1 country
- CRS Clinical Research Services Berlin GmbHBerlin, Germany